PHARMACY

APhA Foundation endows the William H. Briner Award with support from the National Association of Nuclear Pharmacies

BY Antoinette Alexander

WASHINGTON — The American Pharmacists Association Foundation announced from the APhA Annual Meeting and Exposition in San Diego, the completed endowment of the APhA-Academy of Pharmacy Practice and Management William H. Briner Distinguished Nuclear Pharmacy Practice Award with a $37,000 pledge from the National Association of Nuclear Pharmacies.  

"The National Association of Nuclear Pharmacies is proud to be the Premier Supporter of the APhA-APPM William H. Briner Distinguished Achievement Award in Nuclear Pharmacy Practice," said executive director and chairman of NANP, Jeff Norenberg. "Through this support, NANP seeks to ensure the enduring recognition of nuclear pharmacist practitioners who have made distinguished contributions to promote best practices in the specialized practice of nuclear pharmacy. For more than 30 years, the NANP has worked in close partnership with APhA to promote and advance the profession of nuclear pharmacy and to ensure patient access to safe, reliable, and effective radiopharmaceuticals."

Established in 1997, the award was renamed in 2000 in honor of Captain William H. Briner, a radiopharmacist who helped bring the practice of pharmacy to nuclear medicine. The award annually recognizes the achievements of an individual who has made a significant contribution or sustained contributions to the provision of pharmaceutical care within the practice areas represented by the APhA-APPM Section on Nuclear Pharmacy Practice. The 2015 recipient is Richard Nickel, a research pharmacist at Saint Louis University.

"The legacy of Captain Briner lives on through his influence on the principles and procedures of nuclear pharmacy, and through the contributions of the recipients of the award named in his honor," said Mark Soffing, APhA-APPM Nuclear Pharmacy Special Interest Group chair. "We are grateful for the NANP's premier support of the award, which will allow us to continue to recognize practitioners who shape the future of nuclear pharmacy practice."

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?
PHARMACY

Teva to strengthen CNS portfolio with Auspex acquisition

BY Ryan Chavis

JERUSALEM and LA JOLLA, Calif. — Teva Pharmaceutical Industries and Auspex Pharmaceuticals on Monday announced a merger agreement under which Teva will acquire Auspex in an all-cash transaction with an enterprise value of $3.2 billion. In addition to enhancing Teva’s revenue and earnings growth profile, the deal will strengthen its central nervous system franchise thanks to Auspex’s portfolio of medications for people dealing with movement disorders. 
 
"The acquisition of Auspex is a significant step in strengthening Teva’s leadership position in CNS and advances us into underserved movement disorder markets. We look forward to accelerating the development and commercialization of the Auspex portfolio based on our infrastructure, capabilities and strong commercial and R&D position in CNS. As we have outlined recently, one of our key priorities for 2015 is to support Teva’s mid- to long-term growth and create value for our shareholders with business development opportunities that are closely aligned with our core therapeutic areas. This transaction represents a first major step with regards to that commitment and we expect to continue this focus in the future,” said Erez Vigodman, president and CEO of Teva.
 
According to the companies, Auspex’s lead investigational product SD-809 (deutetrabenazine) is being developed for the potential treatment of chorea associated Huntington’s disease, tardive dyskinesia, and Tourette syndrome. 
 
Auspex’s lead candidate, SD-809, offers compelling efficacy and safety benefits to patients, as demonstrated by the impressive Phase 3 topline data in Huntington’s disease announced in December 2014,” said Michael Hayden, MD, PhD, Teva’s president of global research and development and chief scientific officer. “Teva is well positioned to realize the robust IP potential of these investigational products with Auspex’s deuterated technology which could represent a significant breakthrough for patients who often have no sustainable symptom relief from their disease.”
keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?
Press ECS to exit
Zoom
PHARMACY

At the scene of NACDS RxIMPACT Day

BY DSN STAFF

Images courtesy of NACDS

WASHINGTON — More than 350 pharmacy advocates headed to Capitol Hill for the seventh annual NACDS RxIMPACT Day to further reinforce the recognition by lawmakers of the evolving role of pharmacy in patient care and educate members of Congress about pro-patient, pro-pharmacy policy.

During this year’s event, held Wednesday and Thursday, pharmacy advocates conducted more than 450 meetings with members of Congress, meeting with every member of Congress who serves on a Congressional healthcare committee, and with every member of Congress who was newly elected in November 2014.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?